Risk factors for gallbladder cancer and cholangiocarcinoma: Similarities, differences and updates

Journal of Gastrointestinal Cancer

Volumn 43, Issue 2, 2012, Pages 137-147

  Rustagi, Tarun ^a   Dasanu, Constantin A ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Cancer; Cholangiocarcinoma; Cholelithiasis; Gallbladder; Gallstones; Liver fluke; Risk factors

Indexed keywords

NITROSAMINE;

BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER INCIDENCE; CANCER RISK; CHOLELITHIASIS; CLONORCHIS SINENSIS; COMMON BILE DUCT CYST; CONGENITAL MALFORMATION; GALLBLADDER CANCER; GALLSTONE; GENETIC TRAIT; HUMAN; INFECTION; OPISTHORCHIS VIVERRINI; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84863869956     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9284-y     Document Type: Review

References (161)

1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(1 Suppl):171-90.
2. Hamrick Jr RE, Liner FJ, Hastings PR, Cohn Jr I. Primary carcinoma of the gallbladder. Ann Surg. 1982;195(3):270-3. (Pubitemid 12185013)
3. Yamaguchi K, Chijiiwa K, Ichimiya H, Sada M, Kawakami K, Nishikata F, et al. Gallbladder carcinoma in the era of laparoscopic cholecystectomy. Arch Surg. 1996;131(9):981-4. discussion 985.
4. A prospective analysis of 1518 laparoscopic cholecystectomies. The Southern Surgeons Club. N Engl J Med. 1991;324 (16):1073-8.
5. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-49.
6. Diehl AK. Epidemiology of gallbladder cancer: a synthesis of recent data. J Natl Cancer Inst. 1980;65(6):1209-14. (Pubitemid 11196007)
7. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14(2):109-14. (Pubitemid 24153079)
8. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. CA Cancer J Clin. 2006;56(2):106-30.
9. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33(6):1353-7. (Pubitemid 32496970)
10. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472-7. (Pubitemid 38230849)
11. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94(11):1751-8. (Pubitemid 43924943)
12. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98 (12):873-5. (Pubitemid 43923444)
13. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37(6):806- 13.
14. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;2:10.
15. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of intra-and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99(11):895-7. (Pubitemid 47073512)
16. Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, Part 1. Oncology. 2004;18(7):889-96.
17. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology. 2005;128(3):620- 6.
18. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308-11.
19. Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol. 2007;19(8):615-7. (Pubitemid 47067057)
20. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology. 2005;128(6):1655-67. (Pubitemid 40692558)
21. Welzel TM, Mellemkjaer L, Gloria G, Sakoda LC, Hsing AW, El Ghormli L, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer. 2007;120(3):638-41. (Pubitemid 46001359)
22. Hsing AW, Gao YT, Han TQ, Rashid A, Sakoda LC, Wang BS, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer. 2007;97 (11):1577-82. (Pubitemid 350175843)
23. Ahrens W, Timmer A, Vyberg M, Fletcher T, Guenel P, Merler E, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol. 2007;19(8):623-30. (Pubitemid 47067059)
24. Donato F, Gelatti U, Tagger A, Favret M, Ribero ML, Callea F, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12(10):959-64. (Pubitemid 34048878)
25. Okuda K, Kubo Y, Okazaki N, Arishima T, Hashimoto M. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer. 1977;39(1):232-46. (Pubitemid 8029004)
26. Su CH, Shyr YM, Lui WY, P'Eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg. 1997;84(7):969-73.
27. Chijiiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995;130(2):194-7.
28. Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol. 1999;14(12):1144-9.
29. Lee CC, Wu CY, Chen GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol. 2002;17(9):1015-20.
30. Yamamoto K, Tsuchiya R, Ito I, et al. A study of cholangiocarcinoma coexisting with hepatolithiasis. Jpn J Gastroenterol Surg. 1984;17:601.
31. Kinami Y, Noto H, Miyazaki I, et al. A study of hepatolithiasis associated with cholangiocarcinoma. Acta Hepatol Jpn. 1978;19:573.
32. Paraskevopoulos JA, Dennison AR, Ross B, Johnson AG. Primary carcinoma of the gallbladder: a 10-year experience. Ann R Coll Surg Engl. 1992;74(3):222-4.
33. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591-602. (Pubitemid 43376420)
34. Maringhini A, Moreau JA, Melton 3rd LJ, Hench VS, Zinsmeister AR, DiMagno EP. Gallstones, gallbladder cancer, and other gastrointestinal malignancies. An epidemiologic study in Rochester, Minnesota. Ann Intern Med. 1987;107 (1):30-5. (Pubitemid 17098633)
35. Zatonski WA, Lowenfels AB, Boyle P, Maisonneuve P, de Mesquita HB Bueno, Ghadirian P, et al. Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH Program of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997;89(15):1132-8.
36. Ghadirian P, Simard A, Baillargeon J. A population-based case- control study of cancer of the bile ducts and gallbladder in Quebec, Canada. Rev Épidémiol Santé Publique. 1993;41 (2):107-12. (Pubitemid 23152335)
37. Chow WH, Johansen C, Gridley G, Mellemkjaer L, Olsen JH, Fraumeni Jr JF. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer. 1999;79(3- 4):640-4.
38. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4(3):167-76. (Pubitemid 36322307)
39. Glenn F, Hays DM. The scope of radical surgery in the treatment of malignant tumors of the extrahepatic biliary tract. Surg Gynecol Obstet. 1954;99(5):529-41.
40. Sahani D, Prasad SR, Tannabe KK, Hahn PF, Mueller PR, Saini S. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging. 2003;28(1):72-4. (Pubitemid 36460666)
41. Ishikawa Y, Wada I, Fukumoto M. Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. J Environ Pathol Toxicol Oncol. 2001;20 (4):311-5. (Pubitemid 34052128)
42. Taylor GN, Lloyd RD, Mays CW, Angus W, Miller SC, Shabestari L, et al. Plutonium- or americium-induced liver tumors and lesions in beagles. Health Phys. 1991;61(3):337-47.
43. Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-64. (Pubitemid 34232782)
44. Pandey M, Shukla VK. Lifestyle, parity, menstrual and reproductive factors and risk of gallbladder cancer. Eur J Cancer Prev. 2003;12(4):269-72. (Pubitemid 36994080)
45. Darby SC, Whitley E, Howe GR, Hutchings SJ, Kusiak RA, Lubin JH, et al. Radon and cancers other than lung cancer in underground miners: a collaborative analysis of 11 studies. J Natl Cancer Inst. 1995;87(5):378-84.
46. Ellis EF, Gordon PR, Gottlieb LS. Oral contraceptives and cholangiocarcinoma. Lancet. 1978;1(8057):207. (Pubitemid 8273538)
47. Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand Suppl. 1980;500:7-12. (Pubitemid 11214507)
48. Lowenfels AB, Norman J. Isoniazid and bile duct cancer. JAMA. 1978;240(5):434-5.
49. Milne R, Vessey M. The association of oral contraception with kidney cancer, colon cancer, gallbladder cancer (including extrahepatic bile duct cancer) and pituitary tumours. Contraception. 1991;43(6):667-93.
50. The WHO Collaborative Study of neoplasia and steroid contraceptives. Combined oral contraceptives and gallbladder cancer. Int J Epidemiol. 1989;18(2):309-14.
51. Zhou YM, Yin ZF, Yang JM, Li B, Shao WY, Xu F, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol. 2008;14(4):632-5. (Pubitemid 351320834)
52. Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case- control study in the United Kingdom. Br J Cancer. 2009;100 (1):178-80.
53. Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5 (10):1221-8. (Pubitemid 47496233)
54. Shaib YH, El-Serag HB, Nooka AK, Thomas M, Brown TD, Patt YZ, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol. 2007;102(5):1016-21. (Pubitemid 46698225)
55. Mitacek EJ, Brunnemann KD, Hoffmann D, Limsila T, Suttajit M, Martin N, et al. Volatile nitrosamines and tobacco-specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis. 1999;20(1):133-7. (Pubitemid 29033855)
56. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria - an epidemiological investigation. Br J Cancer. 1984;50(3):389-97.
57. Sawanyawisuth K. Genes and cholangiocarcinoma. Southeast Asian J Trop Med Public Health. 2009;40(4):701-12.
58. Konstantinidis IT, Deshpande V, Genevay M, Berger D, Fernandez-del Castillo C, Tanabe KK, et al. Trends in presentation and survival for gallbladder cancer during a period of more than 4 decades: a single-institution experience. Arch Surg. 2009;144(5):441-7. discussion 447.
59. Duffy A, Capanu M, Abou-Alfa GK, Huitzil D, Jarnagin W, Fong Y, et al. Gallbladder cancer (GBC): 10-year experience at memorial Sloan-Kettering cancer centre (MSKCC). J Surg Oncol. 2008;98(7):485-9.
60. Scott TE, Carroll M, Cogliano FD, Smith BF, Lamorte WW. A case-control assessment of risk factors for gallbladder carcinoma. Dig Dis Sci. 1999;44(8):1619-25. (Pubitemid 29434735)
61. Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1498-501.
62. Strom BL, Soloway RD, Rios-Dalenz JL, Rodriguez-Martinez HA, West SL, Kinman JL, et al. Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer. 1995;76 (10):1747-56.
63. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004;4(9):695-706. (Pubitemid 39215068)
64. Miquel JF, Covarrubias C, Villaroel L, Mingrone G, Greco AV, Puglielli L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology. 1998;115(4):937-46. (Pubitemid 28452942)
65. Watanapa P, Watanapa WB. Liver fluke-associated cholangiocarcinoma. Br J Surg. 2002;89(8):962-70. (Pubitemid 34994687)
66. Watanapa P. Cholangiocarcinoma in patients with opisthorchiasis. Br J Surg. 1996;83(8):1062-4. (Pubitemid 26291207)
67. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol. 1996;25(5):933-40.
68. Kim YI. Liver carcinoma and liver fluke infection. Arzneimittelforschung. 1984;34(9B):1121-6.
69. Kurathong S, Lerdverasirikul P, Wongpaitoon V, Pramoolsinsap C, Kanjanapitak A, Varavithya W, et al. Opisthorchis viverrini infection and cholangiocarcinoma. A prospective, case-controlled study. Gastroenterology. 1985;89(1):151-6. (Pubitemid 15057924)
70. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsaard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand. Trop Med Int Health. 2004;9(5):588-94. (Pubitemid 38657284)
71. Lim MK, Ju YH, Franceschi S, Oh JK, Kong HJ, Hwang SS, et al. Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg. 2006;75(1):93-6. (Pubitemid 351627576)
72. Lun ZR, Gasser RB, Lai DH, Li AX, Zhu XQ, Yu XB, et al. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect Dis. 2005;5(1):31-41. (Pubitemid 40037627)
73. Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S, et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer. 1991;48(3):323-8.
74. Haswell-Elkins MR, Mairiang E, Mairiang P, Chaiyakum J, Chamadol N, Loapaiboon V, et al. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer. 1994;59(4):505-9. (Pubitemid 24357275)
75. Honjo S, Srivatanakul P, Sriplung H, Kikukawa H, Hanai S, Uchida K, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer. 2005;117(5):854-60. (Pubitemid 41599908)
76. Choi D, Lim JH, Lee KT, Lee JK, Choi SH, Heo JS, et al. Cholangiocarcinoma and Clonorchis sinensis infection: a case- control study in Korea. J Hepatol. 2006;44(6):1066-73.
77. Lee TY, Lee SS, Jung SW, Jeon SH, Yun SC, Oh HC, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103 (7):1716-20.
78. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010 Mar;101(3):579-85.
79. Nagaoka T, Ohkawa S, Ito Y, Tamai S, Tarao K, Sugimasa Y, et al. A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography. Nippon Shokakibyo Gakkai Zasshi. 1991;88 (6):1369-74.
80. Kobayashi M, Ikeda K, Saitoh S, Suzuki F, Tsubota A, Suzuki Y, et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer. 2000;88(11):2471-7. (Pubitemid 30331952)
81. Lu H, Ye MQ, Thung SN, Dash S, Gerber MA. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J. 2000;113 (12):1138-41.
82. Hsing AW, Zhang M, Rashid A, McGlynn KA, Wang BS, Niwa S, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer. 2008;122(8):1849-53. (Pubitemid 351413433)
83. Liu XF, Zou SQ, Qiu FZ. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int. 2003;2(2):285-9.
84. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol. 2002;17(10):1049-55. (Pubitemid 35013958)
85. Yamamoto S, Kubo S, Hai S, Uenishi T, Yamamoto T, Shuto T, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci. 2004;95 (7):592-5. (Pubitemid 39089641)
86. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009;49(1):116-23.
87. Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer. 2009;100(11):1765-70.
88. Nath G, Singh H, Shukla VK. Chronic typhoid carriage and carcinoma of the gallbladder. Eur J Cancer Prev. 1997;6(6):557- 9.
89. Shukla VK, Singh H, Pandey M, Upadhyay SK, Nath G. Carcinoma of the gallbladder - is it a sequel of typhoid? Dig Dis Sci. 2000;45(5):900-3. (Pubitemid 30238250)
90. Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000;95 (3):784-7. (Pubitemid 30123920)
91. Matsukura N, Yokomuro S, Yamada S, Tajiri T, Sundo T, Hadama T, et al. Association between Helicobacter bilis in bile and biliary tract malignancies: H. bilis in bile from Japanese and Thai patients with benign and malignant diseases in the biliary tract. Jpn J Cancer Res. 2002;93(7):842-7.
92. Metz DC. Helicobacter colonization of the biliary tree: commensal, pathogen, or spurious finding? Am J Gastroenterol. 1998;93(10):1996-8.
93. Fukuda K, Kuroki T, Tajima Y, Tsuneoka N, Kitajima T, Matsuzaki S, et al. Comparative analysis of Helicobacter DNAs and biliary pathology in patients with and without hepatobiliary cancer. Carcinogenesis. 2002;23(11):1927-31. (Pubitemid 35355942)
94. Kobayashi T, Harada K, Miwa K, Nakanuma Y. Helicobacter genus DNA fragments are commonly detectable in bile from patients with extrahepatic biliary diseases and associated with their pathogenesis. Dig Dis Sci. 2005;50(5):862-7. (Pubitemid 40684901)
95. Murata H, Tsuji S, Tsujii M, Fu HY, Tanimura H, Tsujimoto M, et al. Helicobacter bilis infection in biliary tract cancer. Aliment Pharmacol Ther. 2004;20 Suppl 1:90-4. (Pubitemid 39120278)
96. Roa I, Ibacache G, Carvallo J, Melo A, Araya J, De Aretxabala X, et al. Microbiological study of gallbladder bile in a high risk zone for gallbladder cancer. Rev Med Chil. 1999;127(9):1049-55.
97. Lee SS, Kim MH, Lee SK, Jang SJ, Song MH, Kim KP, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer. 2004;100(4):783-93. (Pubitemid 38176857)
98. Taguchi J, Yasunaga M, Kojiro M, Arita T, Nakayama T, Simokobe T. Intrahepatic and extrahepatic biliary papillomatosis. Arch Pathol Lab Med. 1993;117(9):944-7. (Pubitemid 23263831)
99. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol. 1999;30 (1):21-5. (Pubitemid 29037389)
100. Okamoto M, Okamoto H, Kitahara F, Kobayashi K, Karikome K, Miura K, et al. Ultrasonographic evidence of association of polyps and stones with gallbladder cancer. Am J Gastroenterol. 1999;94(2):446-50. (Pubitemid 29084667)
101. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983;118 (8):986-8. (Pubitemid 13026852)
102. Song HK, Kim MH, Myung SJ, Lee SK, Kim HJ, Yoo KS, et al. Choledochal cyst associated the with anomalous union of pancreaticobiliary duct (AUPBD) has a more grave clinical course than choledochal cyst alone. Korean J Intern Med. 1999;14(2):1-8.
103. Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann Surg. 1994;220(5):644-52. (Pubitemid 24355776)
104. Scott J, Shousha S, Thomas HC, Sherlock S. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol. 1980;73(2):113-9. (Pubitemid 10083208)
105. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303-14. (Pubitemid 41416587)
106. Pisano G, Donlon JB, Platell C, Hall JC. Cholangiocarcinoma in a type III choledochal cyst. Aust N Z J Surg. 1991;61(11):855-7.
107. Kale IT, Kuzu MA. Porta choledochal fistula: an unusual complication of a cholangiocarcinoma arising from a type I choledochal cyst. Eur J Surg Oncol. 1997;23(2):188-9. (Pubitemid 27223017)
108. Bova JG, Dempsher CJ, Sepulveda G. Cholangiocarcinoma associated with a type 2 choledochal cyst. Gastrointest Radiol. 1983;8(1):41-3. (Pubitemid 13186725)
109. Robertson JF, Raine PA. Choledochal cyst: a 33-year review. Br J Surg. 1988;75(8):799-801.
110. de Vries JS, de Vries S, Aronson DC, Bosman DK, Rauws EA, Bosma A, et al. Choledochal cysts: age of presentation, symptoms, and late complications related to Todani's classification. J Pediatr Surg. 2002;37(11):1568-73. (Pubitemid 35253596)
111. Ohtsuka T, Inoue K, Ohuchida J, Nabae T, Takahata S, Niiyama H, et al. Carcinoma arising in choledochocele. Endoscopy. 2001;33(7):614-9. (Pubitemid 32618930)
112. Hu B, Gong B, Zhou DY. Association of anomalous pancreaticobiliary ductal junction with gallbladder carcinoma in Chinese patients: an ERCP study. Gastrointest Endosc. 2003;57(4):541-5. (Pubitemid 36402722)
113. Chijiiwa K, Kimura H, Tanaka M. Malignant potential of the gallbladder in patients with anomalous pancreaticobiliary ductal junction. The difference in risk between patients with and without choledochal cyst. Int Surg. 1995;80(1):61-4.
114. Funabiki T, Matsubara T, Ochiai M, Marugami Y, Sakurai Y, Hasegawa S, et al. Surgical strategy for patients with pancreaticobiliary maljunction without choledocal dilatation. Keio J Med. 1997;46(4):169-72. (Pubitemid 128473315)
115. Elnemr A, Ohta T, Kayahara M, Kitagawa H, Yoshimoto K, Tani T, et al. Anomalous pancreaticobiliary ductal junction without bile duct dilatation in gallbladder cancer. Hepatogastroenterology. 2001;48(38):382-6. (Pubitemid 32391572)
116. Sugiyama M, Atomi Y. Anomalous pancreaticobiliary junction without congenital choledochal cyst. Br J Surg. 1998;85 (7):911-6. (Pubitemid 28341558)
117. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999;341(18):1368- 78.
118. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol. 2009;50(1):158-64.
119. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36(3):321-7. (Pubitemid 34194790)
120. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):523-6. (Pubitemid 38524134)
121. de Groen PC. Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? Hepatology. 2000;31(1):247-8.
122. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology. 1998;27(2):311-6. (Pubitemid 28081041)
123. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995;332(14):924-33.
124. Wiesner RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc. 1994;69(10):969-82. (Pubitemid 24310077)
125. Rosen CB, Nagorney DM, Wiesner RH, Coffey Jr RJ, LaRusso NF. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991;213(1):21-5.
126. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610-5. (Pubitemid 26111384)
127. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology. 2000;31(1):7-11. (Pubitemid 30033681)
128. Stauffer MH, Sauer WG, Dearing WH, Baggenstoss AH. The spectrum of cholestatic hepatic disease. JAMA. 1965;191:829- 37.
129. Ham JM. Tumors of biliary epithelium and ulcerative colitis. Ann Surg. 1968;168(6):1088-93.
130. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol. 1997;32 (10):1042-5. (Pubitemid 27433668)
131. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol. 2008;42(2):178-90.
132. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: a meta-analysis. Br J Cancer. 2007;96(9):1457-61. (Pubitemid 46685777)
133. Rai A, Mohapatra SC, Shukla HS. A review of association of dietary factors in gallbladder cancer. Indian J Cancer. 2004;41 (4):147-51. (Pubitemid 40203357)
134. Pandey M, Shukla VK. Diet and gallbladder cancer: a case- control study. Eur J Cancer Prev. 2002;11(4):365-8. (Pubitemid 34948205)
135. Serra I, Yamamoto M, Calvo A, Cavada G, Baez S, Endoh K, et al. Association of chili pepper consumption, low socioeconomic status and longstanding gallstones with gallbladder cancer in a Chilean population. Int J Cancer. 2002;102 (4):407-11. (Pubitemid 35265881)
136. Rai A, Mohapatra SC, Shukla HS. Correlates between vegetable consumption and gallbladder cancer. Eur J Cancer Prev. 2006;15 (2):134-7. (Pubitemid 44145598)
137. Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402-10. (Pubitemid 30396295)
138. Liang HP, Cheung WK, Su FH, Chu FY. Porcelain gallbladder. J Am Geriatr Soc. 2008;56(5):960-1.
139. Towfigh S, McFadden DW, Cortina GR, Thompson Jr JE, Tompkins RK, Chandler C, et al. Porcelain gallbladder is not associated with gallbladder carcinoma. Am Surg. 2001;67(1):7-10. (Pubitemid 33638484)
140. Stephen AE, Berger DL. Carcinoma in the porcelain gallbladder: a relationship revisited. Surgery. 2001;129(6):699-703. (Pubitemid 32493672)
141. Sorensen HT, Friis S, Olsen JH, Thulstrup AM, Mellemkjaer L, Linet M, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology. 1998;28(4):921-5. (Pubitemid 28450250)
142. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89(18):1360-5. (Pubitemid 27418027)
143. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88(20):1472-7. (Pubitemid 26340049)
144. Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995;55 (12):2511-5.
145. Wistuba II, Gazdar AF, Roa I, Albores-Saavedra J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol. 1996;27 (4):360-5. (Pubitemid 26113819)
146. Masuhara S, Kasuya K, Aoki T, Yoshimatsu A, Tsuchida A, Koyanagi Y. Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg. 2000;7(2):198-205.
147. Hidaka E, Yanagisawa A, Seki M, Takano K, Setoguchi T, Kato Y. High frequency of K-ras mutations in biliary duct carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res. 2000;60(3):522-4. (Pubitemid 30094542)
148. Hanada K, Tsuchida A, Iwao T, Eguchi N, Sasaki T, Morinaka K, et al. Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol. 1999;94(6):1638- 42.
149. Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2002;49(45):604-8. (Pubitemid 34615308)
150. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995;109(5):1612-7.
151. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998;29 (2):175-80. (Pubitemid 28099514)
152. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002;40(3):269-78. (Pubitemid 34227118)
153. Tannapfel A, Weinans L, Geissler F, Schutz A, Katalinic A, Kockerling F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci. 2000;45(2):317-24. (Pubitemid 30133893)
154. Diamantis I, Karamitopoulou E, Perentes E, Zimmermann A. p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival. Hepatology. 1995;22(3):774-9.
155. Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg. 2000;7(4):426-31.
156. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer. 1998;82 (1):86-95. (Pubitemid 28070483)
157. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut. 1996;38 (2):265-8. (Pubitemid 26048700)
158. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis. 2004;24(2):139-54. (Pubitemid 38738343)
159. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000;47(5):721-7.
160. Taniai M, Higuchi H, Burgart LJ, Gores GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology. 2002;123(4):1090-8.
161. Momoi H, Okabe H, Kamikawa T, Satoh S, Ikai I, Yamamoto M, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res. 2001;7(9):2648-55. (Pubitemid 32911367)